BENYLIN MUCUS COUGH, BENYLIN CHESTY COUGHS (NON-DROWSY)

Adults and children aged 12 years and over:

Oral. Two 5 ml spoonfuls four times a day. 3).

The Elderly:

As for adults. Hepatic/renal dysfunction Experience with the use of this product suggests that normal adult dosage is appropriate for mild to moderate dysfunction. Caution should be exercised in severe hepatic and severe renal impairment.

[See Pharmacokinetics]. Do not exceed the stated dose. Keep out of the sight and reach of children.

The safety of guaifenesin/menthol is based on available data from clinical trials and adverse drug reactions (ADRs) identified during post-marketing experience are included.

The frequencies are provided according to the following convention:

Very common ≥1/10 Common ≥1/100 and < 1/10 Uncommon ≥1/1,000 and <1/100 Rare ≥1/10,000 and <1/1,000 Very rare <1/10,000, including isolated reports Not known (cannot be estimated from the available data) ADRs are presented for frequency category based on 1) incidence in adequately designed clinical trials or epidemiology studies if available or 2) when incidence cannot be estimated, frequency category is listed as ‘Not known’ Adverse Drug Reactions identified During Clinical trials, Epidemiology studies and Post-Marketing Experience with Guaifenesin.

Frequency Category Estimated from Clinical Trials or Epidemiology Studies. Body system Incidence Reported adverse event Immune System Disorders Not known Hypersensitivity reactions (hypersensitivity, pruritus and urticaria) Rash Gastrointestinal Disorders Not known Abdominal pain upper Diarrhoea Nausea Vomiting Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

This product should not be used for persistent or chronic cough, such as occurs with asthma, or where cough is accompanied by excessive secretions, unless directed by a physician. Caution should be exercised when using the product in the presence of severe renal or severe hepatic impairment, [See Pharmacokinetics].

5 g of glucose and 1 g of sucrose per 5 ml. This should be taken into account in patients with diabetes mellitus. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

This medicine contains 197 mg of alcohol (ethanol) in each 5 ml. The amount in 5 ml of this medicine is equivalent to less than 5 ml beer or 2 ml wine. The small amount of alcohol in this medicine will not have any noticeable effects.

82% of the WHO recommended maximum daily intake of 2 g sodium for an adult. This medicine contains 10 mg sodium benzoate (E 211) in each 5 ml. This product contains Ponceau 4R (E 124) red colouring which may cause allergic reactions.

This product is contraindicated in individuals with known hypersensitivity to the product, or any of its components. Not to be used in children under the age of 12 years.